16 groups write open letter to WHO Director-General Dr Tedros: Roadmap on Access to Medicines and Vaccines 2019-2023

On Friday, 3 August 2018, 16 groups sent an open letter to WHO Director-General, Dr Tedros Adhanom Ghebreyesus expressing views on the proposed WHO Roadmap on Access to Medicines and Vaccines 2019-2023. The letter requested the Director-General to strengthen activities… Continue Reading

Compensation under 28 USC §1498

More on 1498 here: https://www.keionline.org/cl/28usc1498 There is a discussion of compensation under 28 USC §1498 in Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies. UNDP and World Health Organization. 2005 (pages 18-21 in the UNDP edition, and… Continue Reading

Orphan Drug R&D costs

1997 James Love, Call for More Reliable Costs Data on Clinical Trials, The Marketletter, January 13, 1997. 2017 James Love, Orphan Drugs Designations and Approvals have Something to Say about Risks, Bill of Health, September 25, 2017. James Love, What… Continue Reading

KEI’s opening statement at WIPO’s 2017 General Assembly focuses on role of Chief Economist

This was delivered the afternoon on October 3, 2017.

Opening statement of Knowledge Ecology International – WIPO General Assembly 2017

Thank you, Mr. Vice President.

KEI notes the controversies around the world regarding the costs and benefits of intellectual property policies, including in particular extended terms of copyright protection in some countries, access to copyrighted works out of commerce and in teaching and research, and the role of patents in both promoting and discouraging innovation, and creating barriers to access medicine.

Continue Reading

The Blur Banff proposal

Notes on the Blur Banff proposal* KEI Research Note 2013:1 February 1, 2013 This is a brief note on the Blur/Banff proposal for a system of decentralized decision making and competitive intermediaries to provide money to support recorded music that… Continue Reading